Richiedi una copia del documento: Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

Captcha code
Annulla